Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 3/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | RPA1 | P27694 | 1/20 | 0.47 |
| ▸ | PRCP | P42785 | 8/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14740552 | 0.84 | HTT (0.63) | MKNK1MKNK2DRD4DRD2DRD3 | |
| SCHEMBL14985509 | 0.78 | MKNK1 (0.76) | MKNK1MKNK2DRD4DRD2DRD3 | |
| SCHEMBL6169490 | 0.77 | GRM5 (0.45) | — | |
| SCHEMBL14796966 | 0.77 | CPT1A (0.60) | MKNK1MKNK2DRD4DRD2DRD3 | |
| SCHEMBL19806143 | 0.77 | MKNK1 (0.82) | MKNK1MKNK2DRD4DRD2DRD3 | |
| SCHEMBL14686771 | 0.75 | DRD4 (0.69) | DRD4DRD2DRD3USP30CA12 | |
| SCHEMBL2224640 | 0.74 | TRPV1 (0.55) | HTT | |
| SCHEMBL2834580 | 0.74 | USP30 (0.50) | DRD4DRD2DRD3USP30 | |
| SCHEMBL4099888 | 0.74 | RAB9A (0.57) | — | |
| SCHEMBL28774040 | 0.72 | KDM2B (0.41) | DRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | MKNK1 1365/4885MKNK2 2027/4885DRD4 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.